Medical Daily | Novartis phase III study of Afinitor in advanced liver cancer fails to meet ... pharmabiz.com Novartis announced that results of a global phase III study showed that Afinitor (everolimus) did not extend overall survival compared to placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) after progression on or ... Afinitor fails to meet survival endpoint as liver cancer indication Novartis Drug Afinitor Fails In Tests Against Liver Cancer Novartis drug shows no survival benefit in liver cancer |
